143 related articles for article (PubMed ID: 35929455)
1. Impact of Insulin Receptor Substrate-1 rs956115 and CYP2C19 rs4244285 Genotypes on Clinical Outcome of Patients Undergoing Percutaneous Coronary Intervention.
Zong J; Tang Y; Wang T; Ullah I; Xu K; Wang J; Chen P; Chen Z; Zhu T; Chen J; Li J; Wang F; Yang L; Fan Y; Shi L; Gong X; Eikelboom JW; Zhao Y; Li C
J Am Heart Assoc; 2022 Aug; 11(16):e025058. PubMed ID: 35929455
[TBL] [Abstract][Full Text] [Related]
2. Impact of Platelet Endothelial Aggregation Receptor-1 Genotypes on Platelet Reactivity and Early Cardiovascular Outcomes in Patients Undergoing Percutaneous Coronary Intervention and Treated With Aspirin and Clopidogrel.
Xu K; Ye S; Zhang S; Yang M; Zhu T; Kong D; Chen J; Xu L; Li J; Zhu H; Wang F; Yang L; Zhang J; Fan Y; Ying L; Hu X; Zhang X; Chan NC; Li C
Circ Cardiovasc Interv; 2019 May; 12(5):e007019. PubMed ID: 31018667
[TBL] [Abstract][Full Text] [Related]
3. CYP2C19 genotyping combined with on-clopidogrel platelet reactivity in predicting major adverse cardiovascular events in Chinese patients with percutaneous coronary intervention.
Tang XF; Han YL; Zhang JH; Wang J; Yao Y; He C; Xu B; Gao Z; Qiao SB; Chen J; Wu Y; Chen JL; Gao RL; Yang YJ; Yuan JQ
Thromb Res; 2016 Nov; 147():108-114. PubMed ID: 27728892
[TBL] [Abstract][Full Text] [Related]
4. Genotyping, Platelet Activation, and Cardiovascular Outcome in Patients after Percutaneous Coronary Intervention: Two Pieces of the Puzzle of Clopidogrel Resistance.
Siasos G; Oikonomou E; Vavuranakis M; Kokkou E; Mourouzis K; Tsalamandris S; Zaromitidou M; Kioufis S; Tsigkou V; Deftereos S; Stefanadis C; Tousoulis D
Cardiology; 2017; 137(2):104-113. PubMed ID: 28329746
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Impact of
Kim JH; Lee SJ; Cha JJ; Park JH; Hong SJ; Ahn TH; Kim BK; Chang K; Park Y; Song YB; Ahn SG; Suh JW; Lee SY; Cho JR; Her AY; Jeong YH; Kim HS; Kim MH; Shin ES; Lim DS;
J Am Heart Assoc; 2024 May; 13(10):e032248. PubMed ID: 38761068
[TBL] [Abstract][Full Text] [Related]
6. The relationship between on-clopidogrel platelet reactivity, genotype, and post-percutaneous coronary intervention outcomes in Chinese patients.
Tang N; Yin S; Sun Z; Xu X; Qin J
Scand J Clin Lab Invest; 2015 May; 75(3):223-9. PubMed ID: 25594796
[TBL] [Abstract][Full Text] [Related]
7. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.
Shuldiner AR; O'Connell JR; Bliden KP; Gandhi A; Ryan K; Horenstein RB; Damcott CM; Pakyz R; Tantry US; Gibson Q; Pollin TI; Post W; Parsa A; Mitchell BD; Faraday N; Herzog W; Gurbel PA
JAMA; 2009 Aug; 302(8):849-57. PubMed ID: 19706858
[TBL] [Abstract][Full Text] [Related]
8. Clopidogrel response variability: impact of genetic polymorphism and platelet biomarkers for predicting adverse outcomes poststenting.
Golukhova EZ; Ryabinina MN; Bulaeva NI; Grigorian MV; Kubova MCh; Serebruany VL
Am J Ther; 2015; 22(3):222-30. PubMed ID: 25946232
[TBL] [Abstract][Full Text] [Related]
9. Relationship between cytochrome P450 2C19*17 genotype distribution, platelet aggregation and bleeding risk in patients with blood stasis syndrome of coronary artery disease treated with clopidogrel.
Dai ZL; Chen H; Wu XY
Zhong Xi Yi Jie He Xue Bao; 2012 Jun; 10(6):647-54. PubMed ID: 22704413
[TBL] [Abstract][Full Text] [Related]
10. [Relationship between ATP-binding cassette subfamily B member 1 and cytochrome P450 2C19 polymorphisms and the effect of clopidogrel post percutaneous coronary intervention in patients with acute coronary syndrome].
Zhou CF; Ren YH; Song YQ; Yi J; Han BS; Xue Q; Fu ZH; Li DY
Zhonghua Xin Xue Guan Bing Za Zhi; 2016 Apr; 44(4):309-14. PubMed ID: 27112608
[TBL] [Abstract][Full Text] [Related]
11. Variability of platelet response to clopidogrel is not related to adverse cardiovascular events in patients with stable coronary artery disease undergoing percutaneous coronary intervention.
Olędzki S; Kornacewicz-Jach Z; Safranow K; Kiedrowicz R; Gawrońska-Szklarz B; Jastrzębska M; Gorący J
Eur J Clin Pharmacol; 2017 Sep; 73(9):1085-1094. PubMed ID: 28589365
[TBL] [Abstract][Full Text] [Related]
12. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis.
Mega JL; Close SL; Wiviott SD; Shen L; Walker JR; Simon T; Antman EM; Braunwald E; Sabatine MS
Lancet; 2010 Oct; 376(9749):1312-9. PubMed ID: 20801494
[TBL] [Abstract][Full Text] [Related]
13. [Impact of CYP2C19 genotype and platelet function on clinical outcome in coronary atherosclerotic heart diseases patients received clopidogrel post percutaneous coronary intervention].
Wu Y; Zhang XX; Tian L; Jiang JJ; Xu L; Huang YL; Liu H; Li YS
Zhonghua Xin Xue Guan Bing Za Zhi; 2017 May; 45(5):377-385. PubMed ID: 28511321
[No Abstract] [Full Text] [Related]
14. The impact of cytochrome 450 and Paraoxonase polymorphisms on clopidogrel resistance and major adverse cardiac events in coronary heart disease patients after percutaneous coronary intervention.
Zhang Z; Chen M; Zhang L; Zhao Q
BMC Pharmacol Toxicol; 2020 Jan; 21(1):1. PubMed ID: 31900240
[TBL] [Abstract][Full Text] [Related]
15. Effect of high-dose clopidogrel according to CYP2C19*2 genotype in patients undergoing percutaneous coronary intervention- a systematic review and meta-analysis.
Zhang L; Yang J; Zhu X; Wang X; Peng L; Li X; Cheng P; Yin T
Thromb Res; 2015 Mar; 135(3):449-58. PubMed ID: 25511576
[TBL] [Abstract][Full Text] [Related]
16. Pharmacodynamic effect of switching therapy in patients with high on-treatment platelet reactivity and genotype variation with high clopidogrel Dose versus prasugrel: the RESET GENE trial.
Sardella G; Calcagno S; Mancone M; Palmirotta R; Lucisano L; Canali E; Stio RE; Pennacchi M; Di Roma A; Benedetti G; Guadagni F; Biondi-Zoccai G; Fedele F
Circ Cardiovasc Interv; 2012 Oct; 5(5):698-704. PubMed ID: 23048056
[TBL] [Abstract][Full Text] [Related]
17. CYP2C19 Genotype is an Independent Predictor of Adverse Cardiovascular Outcome in Iraqi Patients on Clopidogrel After Percutaneous Coronary Intervention.
Mohammad AM; Al-Allawi NAS
J Cardiovasc Pharmacol; 2018 Jun; 71(6):347-351. PubMed ID: 29554005
[TBL] [Abstract][Full Text] [Related]
18. Cytochrome 2C19 polymorphism and response to adjunctive cilostazol versus high maintenance-dose clopidogrel in patients undergoing percutaneous coronary intervention.
Hwang SJ; Jeong YH; Kim IS; Park KS; Kang MK; Koh JS; Park JR; Park Y; Koh EH; Kwak CH; Hwang JY; Kim S
Circ Cardiovasc Interv; 2010 Oct; 3(5):450-9. PubMed ID: 20823393
[TBL] [Abstract][Full Text] [Related]
19. Comparison of loading with maintenance dose of clopidogrel on platelet reactivity in Chinese with different CYP2C19 genotypes prior to percutaneous coronary intervention.
Zhang X; Yan L; Wang D; Li Y; Han L; Tian L; Liu H; Li Y
Chin Med J (Engl); 2014; 127(14):2571-7. PubMed ID: 25043069
[TBL] [Abstract][Full Text] [Related]
20. [Effects of clopidogrel resistence and CYP2C19 genotype on the clinical prognosis of patients with acute coronary syndrome undergoing percutaneous coronary intervention].
He CB; Li Q; Ye YC; Zhao XL; Tu CC; Zeng Y
Zhonghua Xin Xue Guan Bing Za Zhi; 2020 Sep; 48(9):765-771. PubMed ID: 32957760
[No Abstract] [Full Text] [Related]
[Next] [New Search]
